Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Recursion Pharmaceuticals Inc.
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of REC-1245 for the treatment of participants with unresectable locally advanced or metastatic solid tumors. Participants will receive treatment with REC-1245 for up to 2 years.
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma
Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.
Eastern cooperative oncology group (ECOG) performance status ≤1; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performance Status Scale score of ≥70.
Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 / Lugano criteria and documented by computed tomography (CT) and / or magnetic resonance imaging (MRI)
You may not be if
Received treatment with another RBM39 degrader
Clinically significant gastrointestinal (GI) or GI malabsorption
Clareo Health | A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
